Investor Update

New Phase 3 analyses show that a single dose of REGEN-COV (casirivimab and imdevimab) provides long-term protection against COVID-19

Dear Investor,

Please find attached a press release from our partner Regeneron regarding new follow-up analyses of the 2069 prevention trial that add to the increasing body of evidence supporting the use of Ronapreve to prevent COVID-19:

https://investor.regeneron.com/news-releases/news-release-details/new-phase-3-analyses-show-single-dose-regen-covr-casirivimab-and

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations


 
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com



Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com



Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com


Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
  
Investor Relations North America


 
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com